Cambridge Investment Research Advisors, Inc. Alnylam Pharmaceuticals, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$185.53 - $241.31 $157,514 - $204,872	849 New	849 $202,000
Q2 2022 Jul 13, 2022	SELL	$120.42 - $169.29 $395,579 - $556,117	-3,285 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$127.18 - $173.91 $1,144 - $1,565	9 Added 0.27%	3,285 $536,000
Q4 2021 Feb 03, 2022	SELL	$159.56 - $209.29 $8,935 - $11,720	-56 Reduced 1.68%	3,276 $555,000
Q3 2021 Nov 02, 2021	SELL	$169.75 - $207.73 $205,737 - $251,768	-1,212 Reduced 26.67%	3,332 $629,000
Q2 2021 Aug 10, 2021	BUY	$128.63 - $176.89 $12,219 - $16,804	95 Added 2.14%	4,544 $770,000
Q1 2021 May 07, 2021	BUY	$126.83 - $175.69 $564,266 - $781,644	4,449 New	4,449 $628,000

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$3.97 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.04 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.3 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.26 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.19 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account